Get detailed insights on Pilgrim's Pride Q2 2025 earnings, including 4.3% revenue growth, strategic investments, and expansion plans.

Stryker remains a top-tier competitor in a number of attractive medical markets, including orthopedic implants, surgical instruments, endoscopy, and neurovascular devices. It enjoys a long record of ...

Good morning, and welcome to the Second Quarter of 2025 Pilgrim's Pride Earnings Conference Call and Webcast. [Operator Instructions] At the company's request, this call is being recorded. Please note ...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024; Dupixent ® global net sales (recorded by Sanofi) increased 22% to $4.34 billion ; EYLEA HD ...